Pfizer stock trades at EUR 26.99 ahead of November 3 earnings

Published on 10/23/2026 at 10:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pfizer stock costs EUR 26.99 on October 23, 2026 versus the EUR 27.05 Xetra close. Pfizer reports third-quarter results on November 3, 2026.

Results and dates shape the picture

Pfizer reported USD 15.03 billion in second-quarter revenue on August 4, 2026.
Pfizer raised its full-year 2026 revenue guidance midpoint by USD 500 million.
Pfizer stock trades at EUR 26.99 at 10:38 a.m. CEST at Lang & Schwarz on October 23, 2026, 0.22 percent below the Xetra close of October 22, 2026.

Extreme Nahaufnahme unbeschrifteter weißer Tabletten und Kapseln, Symbolbild für Pfizer Inc — Makroaufnahme unbeschrifteter Tabletten und Kapseln veranschaulicht das Kerngeschäft von Pfizer Inc., ISIN US7170811035, Pharmaindustrie, Illustration mit AI erstellt.

Pfizer Inc. (US7170811035) was trading at EUR 26.99 at Lang & Schwarz on October 23, 2026 at 10:38 a.m. CEST, 0.22 percent below the Xetra close of October 22, 2026 at EUR 27.05. MarketBeat lists November 3, 2026 as the expected date for Pfizer's third-quarter results before the US market opens.

Second-quarter execution supports guidance

Pfizer's latest reported quarter remains the key fundamental reference. On August 4, 2026, revenue reached USD 15.03 billion, according to the Fortune transcript of the company's earnings call. That was an operational increase of 1 percent from the prior-year quarter, while revenue excluding COVID products grew 5 percent operationally.

The same call showed a sharper split between reported and adjusted performance. Adjusted diluted earnings per share were USD 0.77, while reported loss per share was USD 0.04 after USD 4.3 billion in non-cash intangible impairments. The figures make the product mix and one-time charges important for the next update.

What does the guidance change mean?

Management raised the midpoint of full-year 2026 revenue guidance by USD 500 million to a range of USD 60.5 billion to USD 62.5 billion from USD 59.5 billion to USD 60.5 billion, as reported by Fortune. Adjusted diluted earnings per share guidance stayed at USD 2.80 to USD 3.00, including a USD 0.10 impact tied to the Innovent Biologics transaction.

For investors, the November 3 report will test whether stronger non-COVID products can continue to offset lower COVID revenue. MarketBeat puts the third-quarter consensus at USD 15.91 billion of revenue and USD 0.73 of earnings per share, both figures labeled as estimates in its earnings preview.

Upcoming reporting date sets the next checkpoint

The next scheduled checkpoint is November 3, 2026, before the market opens, with the conference call set for 10:00 a.m. ET. Pfizer's investor website also lists a webcast for the November 3 conference call in its communications section.

Stock stays near its yearly high

Pfizer's EUR 26.99 quote sits EUR 0.12 below the EUR 27.11 52-week high and EUR 6.27 above the EUR 20.72 52-week low, based on the same October 23 market snapshot. The current market capitalization was EUR 154.0 billion.

Pfizer was trading at EUR 26.99 at Lang & Schwarz on October 23, 2026 at 10:38 a.m. CEST, 0.22 percent below the Xetra close of October 22, 2026 at EUR 27.05. The further course of trading is shown by the continuously updated real-time quote of Pfizer stock.